BETWEEN EFFICACY AND RISK: A CRITICAL APPRAISAL OF METAMIZOLE’S PHARMACOLOGY, CLINICAL USE AND REGULATORY STATUS
Authors:
- Julia MaszewskaJMJulia Maszewska
- Szymon MilnerowiczSMSzymon Milnerowicz
- Paulina RzepaPRPaulina Rzepa
- Łukasz BrzostŁBŁukasz Brzost
- Marta Danuta CendrowskaMCMarta Danuta Cendrowska
- Beata ChoromańskaBCBeata Choromańska
- Julia ProcykJPJulia Procyk
- Justyna BerentJBJustyna Berent
- Karolina StępieńKSKarolina Stępień
- Barbara PonitkaBPBarbara Ponitka
- Aleksandra KlukowskaAKAleksandra Klukowska
- Wiktoria SzumlińskaWSWiktoria Szumlińska
Open Access
- 30 September 2025
- journal article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(47))
Abstract
This review critically assesses metamizole's pharmacology, clinical efficacy, and safety profile, with particular focus on its widespread over-the-counter (OTC) availability in Poland versus more restrictive approaches elsewhere. The primary research objective was to evaluate whether the clinical benefits of metamizole outweigh its well-documented risks, especially severe adverse effects such as agranulocytosis and immune-mediated liver injury. During the research PubMed, Google Scholar, and institutional sources were used, applying keywords: “pyralgin,” “metamizole,” “analgesic,” “side effects,” “synergy,” and “combination”. Publications from 2000 to 2025 were screened for relevance, with a primary focus on articles in English and Polish. Abstracts were initially analyzed, followed by full-text review; 20 pertinent sources were ultimately selected for appraisal, comparing indications, mechanisms, and interactions with other analgesics, notably paracetamol, NSAIDs, opioids, and gabapentin. Findings demonstrate that metamizole shows unique spasmolytic, analgesic, and antipyretic properties, and offers therapeutic synergism with various analgesic combinations, aiding multimodal pain management when minimizing opioid or NSAID use is preferred. However, serious adverse events, while infrequent, are potentially fatal and unpredictable, with no effective preventive measures or reliable individual risk prediction identified. The review concludes that the unrestricted OTC availability and mass media promotion of metamizole pose disproportionate public health risks. It recommends limiting access to prescription-only status and ending promotional advertising for common ailments, given the availability of safer first-line analgesics.Keywords
This publication has 11 references indexed in Scilit:
- Does Metamizole Cause Less Acute Kidney Injury than Non-Steroidal Anti-Inflammatory Drugs When Combined with Diuretics and Antihypertensives?Toxics, 2025
- Pharmacology and relevant drug interactions of metamizoleBritish Journal of Clinical Pharmacology, 2025
- Influence of Metamizole on Antitumour Activity of Risedronate Sodium in In Vitro Studies on Canine (D-17) and Human (U-2 OS) Osteosarcoma Cell LinesBiomedicines, 2024
- Metamizole-induced agranulocytosis (MIA): a mini reviewMolecular and Cellular Pediatrics, 2023
- One hundred years of dipyrone (metamizole): the recent evidence on its safetyPeer Review, 2023
- Real world evidence of the use of metamizole (dipyrone) by the Brazilian population. A retrospective cohort with over 380,000 patientsEinstein (São Paulo), 2022
- Non-opioid Analgesics and the Endocannabinoid SystemBalkan Medical Journal, 2020
- Metamizole-Associated Adverse Events: A Systematic Review and Meta-AnalysisPLOS ONE, 2015
- The antinociceptive efficacy of morphine, metamizol, or their combination in an experimental rat model with different levels of inflammatory painPharmacology Biochemistry and Behavior, 2008
- Use of intravenous patient-controlled analgesia for the documentation of synergy between tramadol and metamizolBritish Journal of Anaesthesia, 2000